19-May-2010 - Pronota NV

Pronota raises an additional EUR 1.5 million in a final close of its Series B financing totaling EUR 7.9 million

Pronota NV announced that it has raised an additional EUR 1.5 million in the final close of its Series B financing. The financing has been subscribed by MedSciences Capital, the venture capital arm of Kempen & Co, which is a specialized Dutch merchant bank. Pronota has raised a total of EUR 7.9 million in its Series B round, which has been subscribed by premier life sciences investors such as Gimv, Biotech Fund Flanders, LSP, JJDC, KBC Private Equity, VIB, MP Healthcare Venture Management Inc., Baekeland Fund and MedSciences Capital. Pronota is using the proceeds of the Series B financing to push forward its diagnostic development programs in the cardio-renal area, pre-eclampsia, sepsis, and ovarian cancer.

The results obtained so far in its cardio-renal and other programs provide validation of Pronota's technology. Pronota now addresses a range of significant commercial opportunities, and is aiming to have its first product ready for launch in 2012.

Facts, background information, dossiers
More about Pronota
  • News

    Pronota and Molecuence announce collaboration in protein biomarker discovery

    Pronota NV announced that it has entered into an agreement with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical Corporation, to discover and validate protein biomarkers in stroke.  Pronota will apply its  proprietary platforms for protein biomarker discovery (MASSte ... more

    Pronota awarded EUR 1.4 million grant to validate and develop novel cardiovascular biomarkers

    Pronota NV has announced that it has been awarded an EUR 1.4 million grant from IWT (the Institute for the Promotion of Innovation by Science and Technology in Flanders) to further validate and develop novel biomarkers for the management of heart failure. The grant will be used to validate ... more

  • Companies

    Pronota NV

    Pronota (formerly known as Peakadilly) is using its unique capabilities in exploring the proteomes of biological samples to build a portfolio of diagnostic products that work by analysing protein biomarkers in body fluids, typically blood. Some of these products will be designed to help de ... more